Cargando…
Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance
Immune checkpoint inhibitors (ICIs) have changed perspectives for patients with cancer, but come with severe immune-related adverse events (irAEs). To prevent fatality or chronicity, these irAEs are often promptly treated with high-dose immunosuppressants. Until recently, evidence on the effects of...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10182067/ https://www.ncbi.nlm.nih.gov/pubmed/37173424 http://dx.doi.org/10.1038/s41698-023-00380-1 |